Australia-based Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced a USD 600 million convertible bond offering, executing a refinancing of its existing debt structure rather than raising fresh capital for operational expansion. The transaction replaced the majority of Telix's outstanding AUD 650 million convertible bonds due 2029 with a new five-year instrument maturing in April 2031, extending the company's debt runway while resetting coupon terms under current market conditions.
The Telix convertible bonds were upsized from an initial target of USD 550 million to USD 600 million, reflecting demand from eligible investors globally, including both existing and new participants. The notes carry a coupon of 1.5% per annum. The initial conversion price is set at USD 13.85 per ordinary share, equivalent to approximately AUD 19.55, representing a 37.5% premium over the reference share price of AUD 14.22.
Concurrent with the new issuance, Telix conducted a reverse bookbuilding process to repurchase approximately AUD 637 million of its existing AUD 650 million convertible bonds due 2029, representing more than 85% of that outstanding series. Telix stated its intention to exercise its right to redeem the remaining portion of the existing bonds. Settlement of both the new offering and the concurrent repurchase is expected on April 22, 2026, subject to customary conditions. A stock lending agreement was entered into between Elk River Holdings Pty Ltd, as trustee for The Behrenbruch Family Trust, in which Managing Director and Group CEO Dr. Christian Behrenbruch holds an indirect interest, and an affiliate of J.P. Morgan, covering 15 million ordinary shares for a term of 11 months to facilitate the delta placement.
The debt issue follows the January 2026 co-development and commercialization partnership between Telix and Regeneron Pharmaceuticals valued at up to USD 4.3 billion, structured as a 50/50 profit and cost split across global commercialization of radiopharmaceutical cancer therapies and diagnostic assets, with Regeneron paying USD 40 million upfront for four initial programs. In January 2025, Telix completed the acquisition of assets from ImaginAb, Inc. for up to USD 185 million, adding a biologics technology platform and antibody engineering capabilities intended to expand the company's radiotherapeutic reach into new disease areas.
Spot something wrong? Report an issue with this article